Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below: Three Months Ended Years Ended June 30, June 30, 2021 2020 2021 2020 Revenue$19,685,141 $13,713,231 $74,024,073 $62,483,...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Misonix Reports Preliminary Fiscal 2021 Fourth Quarter and Full Year Revenue Results Company Enters into a Definitive Merger Agreement to be Acquired by Bioventus for $518 Million in a Cash-and-Stock Transaction FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes today announced preliminary unaudited fiscal 2021 fourth quarter and full year revenue results for the three- and twelve-month periods ended...
&P 500 Still Bullish, Holding Above Support We continue to see a mixed market environment, but we remain constructive overall considering market dynamics remain largely positive. We explain our outlook below. S&P 500. Despite some FOMC-induced volatility, the S&P 500 held firm above the 4168 short-term support level we noted last week (coinciding with the 50-day MA). As long as 4164-4168 support holds, our target of 4320 remains in play. Should 4164 fail to hold, our next key support level would...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Misonix Appoints Patrick J. Beyer to Board of Directors Leading Medical Tech Executive Brings Extensive Industry Knowledge, Strategic Leadership and Financial Expertise to Board FARMINGDALE, N.Y., May 14, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced its Board of Directors has appointed Patrick J. Beyer as an independent member of the Board. Mr. Beyer joined the Board on May 12, 2021. “Pat is a highly respected, purpo...
Misonix to Participate in Upcoming May and June Virtual Investor Conferences FARMINGDALE, N.Y., May 10, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Chief Executive Officer, Stavros Vizirgianakis, along with Chief Financial Officer, Joe Dwyer, will be participating in the following upcoming virtual investor conferences in May and June: Canaccord Genuity Virtual Musculoskeletal ConferenceDate: Thursday, May 20, 2021Virtual Present...
Misonix Reports Fiscal 2021 Third Quarter Financial Results Misonix Raises Guidance for neXus® Ultrasonic Surgical System to 200 Unit Placements by Fiscal 2021 Year-End FARMINGDALE, N.Y., May 06, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2021 third quarter ended March 31, 2021 as summarized below: Three Months Ended Nine Months Ended March 31, March 31, 2021 2020 2021 2...
Misonix to Report Fiscal 2021 Third Quarter Financial Results and Host Conference Call and Webcast on May 6 FARMINGDALE, N.Y., April 20, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 third quarter financial results after the market closes on Thursday, May 6, 2021. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the general pu...
Misonix Expands Ultrasonic Technology Capabilities to Address the Orthoplastics Market SonicOne® Ultrasonic Wound Debridement Franchise to Provide Comprehensive Procedural Solution for Charcot Foot by Adding Complementary External Fixation Product to Reconstructive Tissue Offering FARMINGDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it has expanded its capabilities to address the orthoplastic...
Misonix Receives Health Canada Approval for neXus FARMINGDALE, N.Y., March 04, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it has received a Health Canada license for the neXus® Ultrasonic Surgical System. This approval confirms that neXus meets the requirements of Health Canada, allowing Misonix to commercialize neXus, along with its various handpieces and disposable products, across Canada. Stavros Vizirgiana...
Misonix to Participate in Upcoming March Investor Conferences FARMINGDALE, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the upcoming Cowen 41st Annual Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference on March 4th and March 16th, respectively. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be available...
Misonix to Participate at Upcoming Investor Conferences FARMINGDALE, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be participating in two upcoming investor conferences. BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools ConferenceDates: February 17th and 18thManagement will host a presentation on Wedne...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Misonix Reports Fiscal 2021 Second Quarter Financial Results FARMINGDALE, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2021 second quarter ended December 31, 2020 as summarized below: Three Months Ended Six Months Ended December 31, December 31, 2020 2019 2020 2019 Revenue$18,256,410 $19,721,986 $35,991,752 $30,867,908 Gross profit$12,991,711 $13,...
Misonix to Report Fiscal 2021 Second Quarter Financial Results and Host Conference Call and Webcast on February 4 FARMINGDALE, N.Y., Jan. 21, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 second quarter financial results after the market closes on Thursday, February 4, 2021. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the...
Misonix to Present at the 39th Annual J.P. Morgan Healthcare Conference FARMINGDALE, N.Y., Dec. 23, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 39th Annual J.P. Morgan Healthcare Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Thursday, January 14th at 3:40 p.m. ET. Management will also be...
Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives FARMINGDALE, N.Y., Dec. 18, 2020 (GLOBE NEWSWIRE) -- 2020) – (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that the second largest U.S. Commercial payer will now cover for all lower extremity dermal wounds. TheraSkin is a proven cellular and tissue-based treatment for difficult to heal chronic wounds....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.